Bank of New York Mellon’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Bank of New York Mellon’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-139	Closed	-$17K	–	4255
2019 Q3	$17K	Hold	139	–	–	﹤0.01%	4192
2019 Q2	$42K	Hold	139	–	–	﹤0.01%	4137
2019 Q1	$63K	Sell	139 -4	-3%	-$1.75K	﹤0.01%	4071
2018 Q4	$65K	Hold	143	–	–	﹤0.01%	4028
2018 Q3	$130K	Hold	143	–	–	﹤0.01%	4001
2018 Q2	$84K	Hold	143	–	–	﹤0.01%	4025
2018 Q1	$93K	Buy	+143	New	+$107K	﹤0.01%	4073
2017 Q4	–	Sell	-173	Closed	-$53K	–	4416
2017 Q3	$53K	Buy	173 +12	+7%	+$4.56K	﹤0.01%	4095
2017 Q2	$77K	Buy	+161	New	+$122K	﹤0.01%	4074

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $299M AUM 53.01% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bank of New York Mellon's HTGM Position: Q4 2019 in Review

Bank of New York Mellon sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 139 shares — an estimated $17K sold.

Bank of New York Mellon first reported a position in HTGM in Q2 2017 and held it in 9 quarters. The position peaked at $130K in Q3 2018. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Bank of New York Mellon reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Bank of New York Mellon sold 139 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $17K.
Bank of New York Mellon first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Bank of New York Mellon's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $130K in Q3 2018.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Bank of New York Mellon's 13F filing for Q4 2019, filed 14 Feb 2020.